Bristol Myers Squibb (CELG-RI) Change in Account Payables (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Change in Account Payables for 18 consecutive years, with -$29.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Change in Account Payables fell 323.08% year-over-year to -$29.0 million; the TTM figure through Jun 2026 stood at $450.0 million (up 533.8% YoY), while the FY2025 annual figure was -$2.0 million, down 101.09% from the prior year.
• Change in Account Payables eased to -$29.0 million in Q2 2026 per CELG-RI's latest filing, from $409.0 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $517.0 million in Q4 2024 and bottomed at -$374.0 million in Q3 2024.
• Historically, Change in Account Payables has averaged $48.3 million across 5 years, with a median of -$3.0 million in 2022.
• On a YoY basis, Change in Account Payables climbed as much as 713.04% in 2023 and fell as far as 768.42% in 2023.
• Bristol Myers Squibb's Change in Account Payables stood at $405.0 million in 2022, then rose by 9.63% to $444.0 million in 2023, then gained by 16.44% to $517.0 million in 2024, then plunged by 117.41% to -$90.0 million in 2025, then surged by 67.78% to -$29.0 million in 2026.
• Business Quant data shows CELG-RI's Change in Account Payables at -$29.0 million in Q2 2026, $409.0 million in Q1 2026, and -$90.0 million in Q4 2025.